ODAC Sides With FDA: Evidence For Elderly AML Drugs Can't Stand On Single-Arm Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Feasible or not, randomized controlled trials are needed before approval of Genzyme's Clolar and Vion's Onrigin to treat elderly acute myeloid leukemia patients.
You may also be interested in...
Eisai Will Make “Totality Of The Evidence” Argument At FDA Panel Review Of Dacogen
Briefing documents for the Oncologic Drugs Advisory Committee’s Feb. 9 meeting suggest Eisai will argue that the totality of the data on decitabine’s efficacy and safety in elderly patients with acute myelogenous leukemia is sufficient to overcome the pivotal trial’s failure to show a statistically significant overall survival benefit in the primary analysis. In contrast, FDA’s review takes a laser-like focus on the failed primary endpoint.
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.